{
  "meta": {
    "title": "29_Drugs_For_Alzheimer_S_Disease_And_Other_Neurodegenerative_Disorders",
    "url": "https://brainandscalpel.vercel.app/29-drugs-for-alzheimer-s-disease-and-other-neurodegenerative-disorders-deae1829.html",
    "scrapedAt": "2025-11-30T12:34:15.928Z"
  },
  "questions": [
    {
      "text": "A 70-year-old male patient is brought to the OPD by his son, with complaints of increasing forgetfulness. Neuroimaging shows marked cortical atrophy of temporal and parietal lobes. What is the most striking neurochemical disturbance in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Deficiency of acetylcholine"
        },
        {
          "id": 2,
          "text": "Deficiency of dopamine"
        },
        {
          "id": 3,
          "text": "Deficiency of serotonin"
        },
        {
          "id": 4,
          "text": "Deficiency of glutamate"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario is suggestive of&nbsp;<strong>Alzheimer's disease (AD)</strong>. The most striking neurochemical disturbance in AD is the <strong>deficiency of acetylcholine </strong>in the subcortical area (especially in the nucleus basalis of Meynert).</p>\n<p>Neurotransmitters like glutamate and 5-HT and other areas of the brain like the hippocampus are also involved in the pathogenesis of this disease.</p>\n<p>The drugs used in Alzheimer's disease are:</p>\n<ul>\n<li><strong>Central acetylcholine esterase inhibitors</strong> targeting acetylcholine deficiency</li>\n<li><strong>NMDA antagonists</strong> targeting glutamate excitotoxicity</li>\n</ul><p>Every year on September 21, we mark World Alzheimer's Day to increase awareness of the prevalent neurological condition that stands as the leading cause of dementia. The theme for 2023, \"Never too early, never too late,\" centers on the significance of identifying and mitigating risk factors, underscoring their vital role in potentially delaying or even averting the development of dementia.</p><hr><h3>Related Pearl: Alzheimer’s disease</h3><p><strong>Alzheimer’s disease:</strong></p>\n<ul>\n<li>Age of onset &gt; 60 years</li>\n<li>Mini-mental state examination (MMSE) &lt; 24</li>\n<li>Diagnosis: Clinical\n<ul>\n<li>2 or more areas of cognitive deficits</li>\n<li>Progressive worsening of memory and other cognitive function</li>\n<li>No disturbance in consciousness</li>\n<li>Other systemic causes must be ruled out </li>\n</ul>\n</li>\n</ul>\n<p><strong>Risk Factors:</strong></p>\n<ul>\n<li>Most important risk factor: Old age</li>\n<li>Other risk factors – Family history, presenilin-1, presenilin-2, Apolipoprotein E4 <strong><strong>(ApoE ε4 allele)</strong></strong>, Ubiquitin, Down syndrome and smoking.</li>\n</ul>\n<p><strong>Protective factors:</strong> NSAIDs and Apolipoprotein <strong>E2</strong></p>\n<p><strong>Causes: </strong>Decrease in <strong>acetylcholine</strong> causing depletion of the cholinergic neurons in the <strong>nucleus basalis of Meynert</strong> resulting in short-term memory defects. </p>\n<p><strong>Early findings:</strong></p>\n<ul>\n<li><strong>Anterograde</strong> memory loss (immediate recall affected, distant memories preserved)</li>\n<li><strong>Visuospatial deficits</strong> (lost in own neighborhood)</li>\n<li><strong>Language difficulties</strong> (difficulty finding words)</li>\n<li><strong>Cognitive impairment</strong> with a progressive decline</li>\n<li>Anosognosia </li>\n<li>Visual processing dysfunction (posterior cortical atrophy syndrome)</li>\n<li>Difficulties with naming and repetition (logopenic aphasia)</li>\n</ul>\n<p><strong>Late findings:</strong></p>\n<ul>\n<li>Psychotic symptoms: <strong>delusions</strong></li>\n<li><strong>Apraxia</strong>: Difficulty to perform learned motor tasks</li>\n<li><strong>Lack of insight</strong> regarding deficits</li>\n<li>Non-cognitive neurologic deficits: Pyramidal and extrapyramidal, myoclonus and seizures</li>\n<li>disrupted sleep - wake pattern.</li>\n<li><strong>Urinary incontinence.</strong></li>\n<li>Loss of procedural memory</li>\n</ul>\n<p><strong>Histopathology:</strong></p>\n<ul>\n<li><strong>Senile plaques</strong> (amyloid deposits), <strong>neurofibrillary tangles</strong> (composed of <strong>tau</strong> proteins), neuronal loss, synaptic loss, and granulovacuolar degeneration of neurons.</li>\n</ul>\n<p>The image below shows neurofibrillary tangles in Alzheimer's disease.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e5db3b220b5c4a6fb0a82d0c724c68c5x640x784.JPEG\" alt=\"Pearl Image\"><p><strong>CT/MRI:</strong></p>\n<ul>\n<li>Later stages: Cortical and subcortical atrophy prominent in parietal and temporal lobes, particularly <strong>hippocampus</strong>. </li>\n</ul>\n<p><strong>Treatment:</strong></p>\n<ul>\n<li>NMDA antagonist: <strong>memantine</strong></li>\n<li>Cholinesterase inhibitors: <strong>donepezil</strong>, <strong>galantamine</strong>, <strong>rivastigmine</strong>.</li>\n<li>Monoclonal antibodies against the N-terminus of the Aβ peptide - <strong>l</strong><strong>ecanemab, donanemab</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2907",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a reversible cholinesterase inhibitor indicated in a patient with Alzheimer's disease?",
      "choices": [
        {
          "id": 1,
          "text": "Donepezil"
        },
        {
          "id": 2,
          "text": "Rivastigmine"
        },
        {
          "id": 3,
          "text": "Galantamine"
        },
        {
          "id": 4,
          "text": "Memantine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Memantine</strong> is an <strong>NMDA receptor antagonist</strong> used to treat moderate to severe dementia in Alzheimer's.</p>\n<p>Donepezil, rivastigmine, and galantamine are reversible cholinesterase inhibitors indicated in Alzheimer's disease. Irreversible antagonists are not indicated in&nbsp;Alzheimer's disease.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1927",
      "difficulty": "medium"
    },
    {
      "text": "A neurology resident changed the current oral medication of a patient with Alzheimer's disease to a transdermal patch of a cholinesterase inhibitor. What must be the new drug that was prescribed?",
      "choices": [
        {
          "id": 1,
          "text": "Tacrine"
        },
        {
          "id": 2,
          "text": "Donepezil"
        },
        {
          "id": 3,
          "text": "Rivastigmine"
        },
        {
          "id": 4,
          "text": "Galantamine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Rivastigmine</strong>&nbsp;is a cholinesterase inhibitor that is available as a <strong>transdermal patch</strong> for use in Alzheimer's disease. It can&nbsp;be applied for over 24 hours. Transdermal delivery <strong>reduces the fluctuation</strong> and avoids direct gastric irritation effects associated with oral formulations.&nbsp;</p>\n<p>Option A: Tacrine is an anticholinesterase that is obsolete because of its association with hepatotoxicity.&nbsp;</p>\n<p>Options B and D: Donepezil and galantamine transdermal formulations are under development and <strong>yet to be available</strong> in the market.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1926",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following NMDA receptor antagonist would you prescribe to a patient with severe Alzheimer's disease?",
      "choices": [
        {
          "id": 1,
          "text": "Memantine"
        },
        {
          "id": 2,
          "text": "Ketamine"
        },
        {
          "id": 3,
          "text": "Piracetam"
        },
        {
          "id": 4,
          "text": "Amantadine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Memantine</strong> is a <strong>noncompetitive</strong> N-methyl-D-aspartate <strong>(NMDA) receptor antagonist </strong>indicated in Alzheimer's disease.<strong>&nbsp;</strong>It<strong>&nbsp;</strong>slows the deterioration of patients with&nbsp;moderate and severe Alzheimer's disease.&nbsp;It is claimed to reduce the excitotoxicity of glutamate.</p>\n<p>Option B - Ketamine is an NMDA receptor antagonist indicated as an anesthetic agent.</p>\n<p>Option C -&nbsp;Piracetam is a nootropic agent (a drug that enhances cognitive function) that is used off-label to enhance memory.</p>\n<p>Option D - Amantadine is an antiviral agent with NMDA receptor antagonistic action which is also indicated in Parkinson's disease due to its action on dopamine release and reuptake.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2909",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is incorrect regarding the management of Alzheimer's disease?",
      "choices": [
        {
          "id": 1,
          "text": "Monoclonal antibodies can be used in the treatment"
        },
        {
          "id": 2,
          "text": "Cholinesterase inhibitors are commonly used"
        },
        {
          "id": 3,
          "text": "Memantine is approved only in moderate to severe disease"
        },
        {
          "id": 4,
          "text": "Cholinesterase inhibitors and memantine have no effect on behavioral and psychiatric symptoms"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Cholinesterase inhibitors</strong> and <strong>memantine</strong> reduce some of the behavioral and psychiatric symptoms in Alzheimer's disease.</p>\n<p>SSRIs like citalopram or benzodiazepines for agitation and atypical antipsychotics for psychiatric symptoms may be considered in severe cases. But atypical antipsychotics in dementia-related psychosis have shown higher mortality. </p>\n<p>Option A - Amyloid beta-directed<strong> monoclonal antibodies</strong> approved for the treatment of Alzheimer's disease are - <strong>l</strong><strong>ecanemab, </strong><strong>donanemab, </strong>aducanumab </p>\n<p>Option B -<strong> Cholinesterase inhibitors</strong> are commonly used and are considered as first-line in <strong>early</strong> or <strong>mild to moderate stages of Alzheimer's disease.</strong> </p>\n<p>Option C -<strong> Memantine</strong> is approved only in <strong>moderate-severe Alzheimer's disease</strong>. There is not enough data to support its use in mild to moderate stages.<br /><br />Note- Aducanumab has been discontinued in the treatment of Alzheimer's</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1929",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old lady came to the OPD with complaints of occasional shock-like sensations down her spine and muscle spasms. T2 weighted MRI shows typical Dawson fingers and oligoclonal bands were detected in the CSF study.  Which of the following is approved for the treatment of her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Interferon alpha"
        },
        {
          "id": 2,
          "text": "Interferon beta"
        },
        {
          "id": 3,
          "text": "Interferon gamma"
        },
        {
          "id": 4,
          "text": "Infliximab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given scenario is suggestive of <strong>multiple sclerosis.&nbsp;</strong><strong>Interferon beta</strong> is approved for use in this condition. It reduces the frequency of attacks in relapsing-remitting multiple sclerosis.</p>\n<p>The probable mechanisms of action of interferon-beta are:</p>\n<ul>\n<li>Immune modulation and a decrease in T cell proliferation.</li>\n<li>Limiting the entry of T cells into CNS.</li>\n<li>Reducing pro-inflammatory and increasing regulatory cytokines.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2902",
      "difficulty": "medium"
    },
    {
      "text": "You plan to start disease-modifying therapy in a 40-year-old patient with relapsing-remitting multiple sclerosis. Which of the following drugs would you not include in the treatment regimen?",
      "choices": [
        {
          "id": 1,
          "text": "Glatiramer acetate"
        },
        {
          "id": 2,
          "text": "Methylprednisolone"
        },
        {
          "id": 3,
          "text": "Fingolimod"
        },
        {
          "id": 4,
          "text": "Cladribine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The disease-modifying therapy of relapsing-remitting multiple sclerosis (MS) does not include <strong>methylprednisolone</strong>. It is used in<strong>&nbsp;acute attacks </strong>and<strong> exacerbations </strong>for MS symptom control<strong>. </strong>The long-term value or disease-modifying potential of glucocorticoid therapy is unknown.&nbsp;</p>\n<p>FDA approved disease-modifying therapy of relapsing-remitting multiple sclerosis are:</p>\n<ul>\n<li>Interferon-beta 1a&nbsp;</li>\n<li>Interferon-beta 1b&nbsp;</li>\n<li>Glatiramer&nbsp;</li>\n<li>Dimethyl fumarate&nbsp;</li>\n<li>Teriflunomide</li>\n<li>Alemtuzumab</li>\n<li>Natalizumab&nbsp;</li>\n<li>Fingolimod&nbsp;</li>\n<li>Mitoxantrone&nbsp;</li>\n<li>Cladribine&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2903",
      "difficulty": "medium"
    },
    {
      "text": "John Cunningham (JC) virus antibody titer is being measured in a patient with multiple sclerosis. During treatment with which of the following drugs are the titres mandatory?",
      "choices": [
        {
          "id": 1,
          "text": "Alemtuzumab"
        },
        {
          "id": 2,
          "text": "Natalizumab"
        },
        {
          "id": 3,
          "text": "Glatiramer"
        },
        {
          "id": 4,
          "text": "Interferon"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>John Cunningham (JC) virus antibody titre</strong> measurement is mandatory during treatment with monoclonal antibodies like<strong> natalizumab</strong>. Progressive multifocal leukoencephalopathy <strong>(PML)</strong> is a life-threatening disease caused by the JC virus in patients with multiple sclerosis.</p>\n<p>It is more common when the patient is <strong>immunocompromised</strong> during their treatment with natalizumab. The current recommendation is to start natalizumab only in a patient who tests negative for JC antibodies.</p>\n<p>Seroconversion can occur anytime during treatment. <strong>Regular monitoring</strong> for JC antibody<strong> every 6 months</strong> is recommended in JC antibody-negative patients on natalizumab.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2904",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old lady presents with complaints of sudden, involuntary, and uncontrollable dance-like movements. Her mother had also developed similar symptoms at the age of 40.  Which of the following drugs is indicated for the treatment of the involuntary movements associated with her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Benzhexol"
        },
        {
          "id": 2,
          "text": "Tetrabenazine"
        },
        {
          "id": 3,
          "text": "Tetrahydrazoline"
        },
        {
          "id": 4,
          "text": "Benztropine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This patient is most likely suffering from <strong>chorea </strong>associated with<strong> Huntington's disease,&nbsp;</strong>for which <strong>tetrabenazine</strong> is indicated. It&nbsp;is a reversible inhibitor of vesicular monoamine transporter-2 (<strong>VMAT-2</strong>).</p>\n<p>Other drugs used in Huntington's disease are:</p>\n<ul>\n<li><strong>Reserpine</strong>,&nbsp;an irreversible inhibitor of VMAT-2 and a longer-acting agent as compared to tetrabenazine.</li>\n<li class=\"ng-binding\"><strong>Deutetrabenazine</strong>&nbsp;refers to deuterium attached to carbon in place of hydrogen, in tetrabenazine (deuterated tetrabenazine).&nbsp;It is a&nbsp;<strong>newer form </strong>of tetrabenazine approved for the treatment of chorea associated with Huntington's disease. It slows down its metabolism, hence it is <strong>longer acting than tetrabenazine</strong>. It is associated with better control of chorea.</li>\n</ul>\n<p>Option A - Benzhexol is a central anticholinergic indicated in parkinsonism.</p>\n<p>Option C - Tetrahydrozoline is a topical alpha-adrenergic agonist indicated for the relief of conjunctival congestion.</p>\n<p>Option D -&nbsp;Benztropine&nbsp;is a muscarinic receptor antagonist that can be used for the management of acute dystonia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2910",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a mechanism of action of Riluzole?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of glutamate release"
        },
        {
          "id": 2,
          "text": "Inhibition of GABA reuptake"
        },
        {
          "id": 3,
          "text": "NMDA glutamate receptor antagonism"
        },
        {
          "id": 4,
          "text": "Kainate glutamate receptor antagonism"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Riluzole does not act by causing inhibition of GABA reuptake.</p>\n<p><strong>Riluzole</strong> is the only drug known to <strong>improve survival </strong>in amyotrophic lateral sclerosis (<strong>ALS</strong>), also known as Lou Gehrig's disease. The mechanism of action involves the&nbsp;<strong>reduction of glutamate-induced excitotoxicity</strong> by:</p>\n<ul>\n<li>Inhibition of glutamate release</li>\n<li>Antagonism of NMDA and kainate-type glutamate receptor&nbsp;</li>\n<li>Direct action on the voltage-dependent sodium channels.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2895",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following new drugs has been approved for the treatment of amyotrophic lateral sclerosis?",
      "choices": [
        {
          "id": 1,
          "text": "Edaravone"
        },
        {
          "id": 2,
          "text": "Piracetam"
        },
        {
          "id": 3,
          "text": "Dabrafenib"
        },
        {
          "id": 4,
          "text": "Trametinib"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Edaravone</strong> was approved by the FDA for the treatment of&nbsp;amyotrophic lateral sclerosis (<strong>ALS</strong>).</p>\n<p>It has <strong>free radical scavenging properties</strong> that may reduce oxidative stress. The exact mechanism of action is unknown. It is to be administered as an IV infusion&nbsp;with an initial treatment cycle of daily dosing for 14 days, followed by a 14-day drug-free period. Subsequent treatment cycles consist of dosing on 10 of 14 days, followed by a 14 day drug-free period.</p>\n<p>The major adverse effect of edaravone is&nbsp;hypersensitivity because the infusion contains sodium bisulfite. Other adverse effects include bruising, gait disorder, and headache.</p>\n<p><strong>Tafinlar (dabrafenib)</strong> and <strong>Mekinist (trametinib)</strong>, are both indicated as monotherapy in&nbsp;BRAF V600E/K (BRAF V600E mutation-positive) melanoma. They are approved for combined administration, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or that has spread to other parts of the body (metastatic).</p>\n<p><strong>Piracetam</strong> is a nootropic agent (a drug that enhances cognitive function) that is used off-label to enhance memory. It is also used to treat myoclonus.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3440",
      "difficulty": "medium"
    }
  ]
}